Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAAShell Companies
+$0.00 today
- Market cap
- $264.62M
- Beta
- 0.00
- P/E (TTM)
- 36.7
- EPS (TTM)
- $0.29
Volume 0.00M
Average 0.11M
DMAA Other Financing Activities
Financing cash flows not reported separately.
Drugs Made In America Acquisition Corp. Ordinary SharesNASDAQ: DMAA
Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026
Other financing activities outflow shrinks to $0
Q1 FY2026 other financing activities was $0, compared with $250.82K a year earlier. Trailing-twelve-month other financing activities was $231.44M.
What to watch
Whether quarterly other financing activities holds near $0 or moves back toward the trailing-twelve-month quarterly average of $57.86M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- 543.97K USD
- Year-over-year change
- +54397200.0%
- 1-year CAGR
- +54397200.0%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 543.97K | +54397200.0% |
| FY2024 | 2024-12-31 | 1 | — |
Other Financing Activities vs competitors
How DMAA compares with its peers on the latest reported figures
- DMAA's LTM Mar 2026 other financing activities of $231.44M is the largest of the 10 companies compared; the peer median is $318.66K.
- Its year-over-year change of +68347.3% is the highest of 2, against a peer median of +21.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $231.44M | +68347.3% | — | — | |
| LTM Mar 2026 | $121.59M | — | — | — | |
| LTM Mar 2026 | $15.09M | — | — | — | |
TACHTitan Acquisition Corp. | LTM Mar 2026 | $5.1M | — | — | — |
TACOUBerto Acquisition Corp. Unit | FY2025 | $1.47M | — | — | — |
| FY2025 | $1.47M | — | — | — | |
| LTM Mar 2026 | $702.26K | +21.6% | — | — | |
OYSEOyster Enterprises II Acquisition Corp | FY2025 | $348K | — | — | — |
| FY2025 | $318.66K | — | — | — | |
| FY2025 | $0 | — | — | — | |
| Peer median (excluding DMAA) | $318.66K | +21.6% | — | — | |
Competitors are the stored peer set for DMAA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Net Income | (479) | 3.97M |
| Depreciation & Amortization | 0 | 0 |
| Deferred Income Tax | 0 | 0 |
| Stock-Based Compensation | 0 | 0 |
| Change in Working Capital | 132 | 138.85K |
| Accounts Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Accounts Payables | 0 | 144.9K |
| Other Working Capital | 132 | (6.05K) |
| Other Non-Cash Items | (171.92K) | (4.65M) |
| Operating Cash Flow | (295) | (539.19K) |
| Capital Expenditures | 5 | 0 |
| Acquisitions (Net) | 0 | 0 |
| Purchases of Investments | 0 | 0 |
| Sales of Investments | 0 | 0 |
| Other Investing Activities | 0 | (231.15M) |
| Investing Cash Flow | 0 | (231.15M) |
| Debt Repayment | 502.21K | (900K) |
| Common Stock Issued | (328.6K) | 232.05M |
| Common Stock Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Other Financing Activities | 1 | 543.97K |
| Financing Cash Flow | 173.62K | 231.69M |
| Effect of Forex Changes | 0 | 0 |
| Net Change in Cash | 1.35K | 4.79K |
| Free Cash Flow | (295) | (539.19K) |
Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAA
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.